X-RAY STUDIES OF SOD IN AMYOTROPHIC LATERAL SCLEROSIS

SOD 在肌萎缩侧索硬化症中的 X 射线研究

基本信息

项目摘要

Eucaryotic copper-zinc superoxide dismutases (CuZnSODs) are 32 kDa homodimeric metalloproteins that catalyze the conversion of superoxide radical to molecular oxygen and hydrogen peroxide. The enzyme is particularly abundant in spinal tissue and red blood cells in mammals. Approximately 60 different single site mutations in human CuZnSOD have individually been linked to an inherited (familial) form of amyotrophic lateral sclerosis (FALS or Lou Gehrig's disease). The disease is characterized by progressive paralysis resulting from motor neuron degeneration and death. Trangenic mouse, neuronal cell culture, and in-vitro studies suggest strongly that a copper-mediated toxic gain of function instead of a loss of superoxide disproportionation activity is responsible for disease onset in individuals heterozygous for any one of the FALS CuZnSOD mutations. Many of these human FALS mutants have been prepared in the laboratory and have been found to have aberrant metal binding properties relative to wild type CuZnSOD. The new properties of the FALS mutant proteins will likely be linked to the gain of the toxin function involved in FALS causation. A recently discovered class of molecules termed "copper chaperones for SOD" (CCS) are responsible for sequestering reactive copper ion from the cellular environment and inserting it correctly into newly translated SOD apoprotein. Because the toxic gain of function of FALS mutant SODs appears to be copper-mediated, a search for inhibitors of the copper chaperone may represent a novel therapeutic avenue for FALS. The primary objectives of this proposal are to generate three-dimensional, atomic resolution structural information on the human and yeast FALS mutants and mutant protein analogs, their respective copper chaperones, and their complexes via the well-established tools of X-ray diffraction and analytical ultracentrifugation. Specifically, we shall: (1) compare and contrast the FALS structures with normal human CuZnSOD and yeast FALS mutant analog structures. (2) use X- radiation from synchroton sources tuned to copper and zinc absorption edges to determine the location and amount of these ions in the metal binding sites of remetallated and as-isolated FALS CuZnSODs, (3) illuminate the postulated interaction of peroxynitrite with normal and FALS mutant CuZnSOD proteins by determining their structures when exposed to peroxynitrite, (4) determine and analyze the structures of several species of CCS molecules alone and in complex with wild type and FALS mutant CuZnSODs, and elucidate the solution properties of these molecules and their complexes under different conditions using contemporary analytical ultracentrifugation methods. These studies will not only promote understanding of the molecular causes of FALS, but also will provide fundamental information on copper ion homeostasis and trafficking at the level of protein- protein interactions.
真核生物铜锌超氧化物歧化酶(cuznsod)是一种32 kDa的二聚体金属蛋白,可催化超氧化物自由基转化为分子氧和过氧化氢。这种酶在哺乳动物的脊髓组织和红细胞中含量尤其丰富。人类CuZnSOD中大约有60种不同的单位点突变分别与遗传性(家族性)肌萎缩性侧索硬化症(FALS或Lou Gehrig's病)有关。该病的特点是运动神经元退化和死亡导致进行性瘫痪。转基因小鼠、神经元细胞培养和体外研究强烈表明,铜介导的毒性功能获得,而不是超氧化物歧化活性的丧失,是导致任何一种FALS CuZnSOD突变杂合个体发病的原因。许多这些人类FALS突变体已经在实验室中制备,并且已经发现与野生型CuZnSOD相比具有异常的金属结合特性。FALS突变蛋白的新特性可能与FALS病因中涉及的毒素功能的获得有关。最近发现的一类分子被称为“SOD铜伴侣”(CCS),它们负责将活性铜离子从细胞环境中隔离出来,并将其正确插入新翻译的SOD载脂蛋白中。由于FALS突变sod的功能毒性增加似乎是铜介导的,因此寻找铜伴侣抑制剂可能代表了FALS的新治疗途径。本研究的主要目的是通过成熟的x射线衍射和分析超离心工具,生成人类和酵母FALS突变体和突变蛋白类似物、它们各自的铜伴侣及其复合物的三维原子分辨率结构信息。具体而言,我们将:(1)将FALS结构与正常人CuZnSOD和酵母FALS突变类似结构进行比较和对比。(2)利用调谐到铜和锌吸收边缘的同步子源的X射线来确定这些离子在再金属化和分离的FALS CuZnSOD的金属结合位点的位置和数量;(3)通过测定暴露于过氧亚硝酸盐时正常和FALS突变CuZnSOD蛋白的结构,阐明了假设的过氧亚硝酸盐与正常和突变CuZnSOD蛋白的相互作用;(4)测定和分析几种CCS分子单独和与野生型和FALS突变型cuznsod复合物的结构,并利用现代分析超离心方法阐明这些分子及其复合物在不同条件下的溶液性质。这些研究不仅将促进对FALS的分子原因的理解,而且将在蛋白质-蛋白质相互作用水平上提供铜离子稳态和运输的基础信息。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Peter JOHN HART其他文献

Peter JOHN HART的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Peter JOHN HART', 18)}}的其他基金

Structure-guided redesign of an antischistosomal drug
抗血吸虫药物的结构引导重新设计
  • 批准号:
    9094447
  • 财政年份:
    2015
  • 资助金额:
    $ 21.68万
  • 项目类别:
The Intron Debranching Enzyme (Dbr1) in Amyotrophic Lateral Sclerosis
肌萎缩侧索硬化症中的内含子脱支酶 (Dbr1)
  • 批准号:
    8733978
  • 财政年份:
    2014
  • 资助金额:
    $ 21.68万
  • 项目类别:
Structure and action of CARDS toxin
卡毒素的结构和作用
  • 批准号:
    8182002
  • 财政年份:
    2011
  • 资助金额:
    $ 21.68万
  • 项目类别:
MOUSE SOD1 AND HUMAN/MOUSE SOD1 CHIMERAS
小鼠 SOD1 和人/小鼠 SOD1 嵌合体
  • 批准号:
    8361708
  • 财政年份:
    2011
  • 资助金额:
    $ 21.68万
  • 项目类别:
Nascent SOD1 in Amyotrophic Lateral Sclerosis
肌萎缩侧索硬化症中的新生 SOD1
  • 批准号:
    8397508
  • 财政年份:
    2009
  • 资助金额:
    $ 21.68万
  • 项目类别:
Nascent SOD1 in Amyotrophic Lateral Sclerosis
肌萎缩侧索硬化症中的新生 SOD1
  • 批准号:
    8195922
  • 财政年份:
    2009
  • 资助金额:
    $ 21.68万
  • 项目类别:
Nascent SOD1 in Amyotrophic Lateral Sclerosis
肌萎缩侧索硬化症中的新生 SOD1
  • 批准号:
    7791079
  • 财政年份:
    2009
  • 资助金额:
    $ 21.68万
  • 项目类别:
Nascent SOD1 in Amyotrophic Lateral Sclerosis
肌萎缩侧索硬化症中的新生 SOD1
  • 批准号:
    7907877
  • 财政年份:
    2009
  • 资助金额:
    $ 21.68万
  • 项目类别:
CRYSTAL STRUCTURE OF YEAST NAD-SPECIFIC ISOCITRATE DEHYDROGENASE
酵母 NAD 特异性异柠檬酸脱氢酶的晶体结构
  • 批准号:
    7726261
  • 财政年份:
    2008
  • 资助金额:
    $ 21.68万
  • 项目类别:
CRYSTAL STRUCTURE OF YEAST NAD-SPECIFIC ISOCITRATE DEHYDROGENASE
酵母 NAD 特异性异柠檬酸脱氢酶的晶体结构
  • 批准号:
    7602328
  • 财政年份:
    2007
  • 资助金额:
    $ 21.68万
  • 项目类别:

相似海外基金

Amyotrophic Lateral Sclerosis: treating the circuit behind the disease
肌萎缩侧索硬化症:治疗疾病背后的回路
  • 批准号:
    MR/Y014901/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.68万
  • 项目类别:
    Research Grant
Dysregulation of RNA processing as a driver of motor neuron dysfunction in Amyotrophic Lateral Sclerosis
RNA 加工失调是肌萎缩侧索硬化症运动神经元功能障碍的驱动因素
  • 批准号:
    MR/Y014286/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.68万
  • 项目类别:
    Research Grant
Fasciculation IN Amyotrophic Lateral Sclerosis Using MUMRI (FINALSUM)
使用 MUMRI 治疗肌萎缩侧索硬化症的肌束颤动 (FINALSUM)
  • 批准号:
    MR/Y503502/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.68万
  • 项目类别:
    Research Grant
I-Corps: Developing A Blood-Based Biomarker for the Detection and Monitoring of Amyotrophic Lateral Sclerosis
I-Corps:开发一种基于血液的生物标志物,用于检测和监测肌萎缩侧索硬化症
  • 批准号:
    2317745
  • 财政年份:
    2023
  • 资助金额:
    $ 21.68万
  • 项目类别:
    Standard Grant
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
  • 批准号:
    10696512
  • 财政年份:
    2023
  • 资助金额:
    $ 21.68万
  • 项目类别:
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
  • 批准号:
    10759808
  • 财政年份:
    2023
  • 资助金额:
    $ 21.68万
  • 项目类别:
Metrics for Brain Controlled Communication: A comprehensive review of clinical outcome assessments for communication brain computer interfaces in amyotrophic lateral sclerosis
脑控制通信指标:肌萎缩侧索硬化症通信脑机接口临床结果评估的全面综述
  • 批准号:
    10848139
  • 财政年份:
    2023
  • 资助金额:
    $ 21.68万
  • 项目类别:
Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
解决神经元 STING 在肌萎缩侧索硬化症和额颞叶痴呆中的作用
  • 批准号:
    10606865
  • 财政年份:
    2023
  • 资助金额:
    $ 21.68万
  • 项目类别:
The Gut Microbiota as a Contributor to Sexual Dimorphism in Amyotrophic Lateral Sclerosis
肠道微生物群是肌萎缩侧索硬化症性别二态性的一个促成因素
  • 批准号:
    488892
  • 财政年份:
    2023
  • 资助金额:
    $ 21.68万
  • 项目类别:
    Operating Grants
The biochemical stratification of amyotrophic lateral sclerosis
肌萎缩侧索硬化症的生化分层
  • 批准号:
    MR/Y001095/1
  • 财政年份:
    2023
  • 资助金额:
    $ 21.68万
  • 项目类别:
    Fellowship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了